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At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine
(PPPM). Individual patients will participate in more aspects of their healthcare. During the development of PPPM, many
rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of
the patient and hence a better quality of life. Coordination of the various activities among different healthcare
professionals in primary, secondary, and tertiary care requires well-defined competencies, implementation of training
and educational programs, sharing of data, and harmonized guidelines. In this position paper, the current knowledge
to understand cancer predisposition and risk factors, the cellular biology of cancer, predictive markers and treatment
outcome, the improvement in technologies in screening and diagnosis, and provision of better drug development
solutions are discussed in the context of a better implementation of personalized medicine. Recognition of the major
risk factors for cancer initiation is the key for preventive strategies (EPMA J. 4(1):6, 2013). Of interest, cancer predisposing
syndromes in particular the monogenic subtypes that lead to cancer progression are well defined and one should focus
on implementation strategies to identify individuals at risk to allow preventive measures and early screening/diagnosis.
Implementation of such measures is disturbed by improper use of the data, with breach of data protection as one of
the risks to be heavily controlled. Population screening requires in depth cost-benefit analysis to justify healthcare costs,
and the parameters screened should provide information that allow an actionable and deliverable solution, for better
healthcare provision.
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A new paradigm shift in cancer prevention and treat-
ment is occurring in terms of predictive, preventive, and
personalized medicine (PPPM) [1]. A patient will partici-
pate in, and be responsible for, more aspects of their
healthcare. During the development of PPPM, many
rapid, specific, and sensitive new methods for early de-
tection of cancer will lead to a more efficacious and less
onerous management of the patient, with better quality
of life. This paper aims to develop the concept, principle,
strategy, and technique for PPPM in cancer.
An important goal is to accurately diagnose, as soon as
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unless otherwise stated.initiated to improve odds of recovery and to improve qual-
ity of life. Currently, healthcare systems utilize screening
programs that incorporate genetic testing to promote early
diagnosis and assess risk to genetic disease in an effort to
prevent illness and hence reduce the burden on healthcare
systems. Screening programs identify susceptible individ-
uals/families eligible for preventive measures and recruit
patients for treatment at early stages of the disease, as ex-
emplified by BRCA1/2 screening. Screening programs aim
to reduce recruitment of patients at advanced stage of the
disease in order to enhance the effectiveness of healthcare.
In addition to preventive genetics, early detection and
monitoring of resistance to therapy, genotype-guided pre-
scription, and dosing provides information to improve tol-
erability of anticancer treatments. Adverse drug reactions
and death by toxicity of chemotherapy is a catastrophicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be prevented [2].
Cancer and public health
Cancer incidence worldwide
The burden of cancer on public health is significantly
high, with more than 14 million new cases worldwide,
8.4 million deaths, and a 5-year cancer prevalence of
more than 35 million in 2012 (Figure 1). Considering a
worldwide population of 7 billion in 2012, the preva-
lence percent is 0.5. Although all cancers are, of course,
extremely important, focus is needed. The most fre-
quently occurring forms of cancer in the EU are colorec-
tal, breast, prostate, and lung cancers. Figure 1 shows
the incidence, mortality, and prevalence in 2012 by gen-
der. Breast cancer is ranked as the most prevalent cancer
in most countries globally, as indicated by the higher
prevalence of cancer in women (Figure 1). In general,
the numbers of deaths follow the numbers of cases,
when comparing developed and less-developed regions.
Of interest, the 5-year cancer prevalence is higher in
men from developed regions, most probably reflecting
the significant decrease in mortality in prostate cancer.
The healthcare burden of non-communicable diseases
Non-communicable diseases (NCDs), or chronic diseases,
are defined as non-transmissible diseases and include can-
cer, cardiovascular disease, respiratory disease, and dia-
betes. NCDs cause 36 million deaths globally, and of the
four main NCDs, cancer is the second most common
cause of death (at 7.9 million per year), almost a quarter of
the total. In addition, NCDs account for 80% of deaths in
low-to-moderate income countries [3]. Studies on the eco-
nomic burden of healthcare (as measured by disability-
adjusted life years (DALYs)) have shown that, while NCDs
comprise 45% of the DALYs, the international fundingFigure 1 Worldwide incidence, mortality and 5 year prevalence in 2012. Dinvested towards them has historically been disproportion-
ately low, at less than 5% (Figure 2) [4].
In terms of a globally aging population, cancer is be-
coming a major burden on healthcare systems, and it
has been established that various lifestyle factors are at-
tributable to cancer, including physical inactivity, high-
fat/low-fiber diets, obesity, smoking, and use or alcohol
misuse [5]. It is known that one-third of cancers are pre-
ventable via addressing lifestyle risk factors. Therefore,
multifaceted approaches are needed to address these is-
sues, e.g., evidence-based strategies to lessen misuse of
alcohol, among others [5].
Rapid increases in NCDs, such as cancer, are consid-
ered to be a threat to poverty-reduction initiatives in
lower-income countries, where access to healthcare re-
sources is limited and paying for healthcare pushes poor
families further into debt. As a consequence, the global
cancer burden (GCB) is expected to rise significantly
and will disproportionately affect the less-developed
world (LDW). In 2011, The United Nations General
Assembly convened a high-level meeting on NCDs to
look at their impact globally, in order to address this
healthcare problem [6]. This meeting by the UN identi-
fied three priority areas for the 193 Member States to
take. These included (1) surveillance and monitoring, (2)
reduction of risk factors (e.g., tobacco and alcohol mis-
use, unhealthy diets and physical inactivity), and (3) a
healthcare element in order to address those currently
suffering with NCDs. Although it should be noted that
some initiatives may eventually go beyond the remit of
the general healthcare sector. For example, in order to
diminish NCDs, engagement with sectors such as fi-
nance, industry, and commerce will be necessary.
Recent work by Love et al. (2010) highlights the com-
plexity of healthcare delivery for oncology and cites that
the multiple challenges are entrenched in socio-economic,ata taken from GLOBOCAN [390] and prevalence data from [391].
Figure 2 Disease burden versus aid (adapted from [4]).
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ternational Cancer Expert Corps (ICEC) have recently
highlighted the (currently limited) availability of training
and career opportunities in global health [8], while also
highlighting the ethical aspects of addressing healthcare
for low-to-middle income nations. Given the complexity
of (a) addressing cancer as a globally increasing NCD and
(b) ethically apportioning healthcare investment, it seems
that a holistic approach is necessary in which policy-
makers and science/medical innovators should combine
strategies to address this socio-economic challenge.
Moreover, the implicit economic costs of personalized
medicine (e.g., targeted cancer therapy using molecular
profiling) will also prove to be a challenge to healthcare
providers worldwide. In order to address these chal-
lenges, international collaborations will be essential to
determine the best and most cost-effective use of tar-
geted therapies. These issues are under discussion by
numerous studies, including Arnedos et al. (2014), who
recently cited the need for “new organizational and
medico-economics approaches” to reduce the financial
burden presented by personalized medicine [9].
Worldwide, an increase in the yearly incidence of can-
cer occurs, from the current 14 million to an estimated
22.2 million by 2030 [10]. Of this figure, 13.1 million
deaths have been predicted. An interesting perspectivehas been added to the debate by Gulley and Morgan
(2014) who cite how the high cancer prevalence and
mortality prevalent in developing nations might be ad-
dressed more efficiently [11]. For instance, because al-
most 25% of these cancers are infection-related, they
postulate that the increased use of molecular assays pro-
vide a cost-effective method to detect relevant pathogen
genomes [11]. Moreover, previous successful business
models, such as the Yunus’ social business model [12],
might also highlight business prototypes that could be
applicable to oncology healthcare activities. Although
beyond the remit of this current paper, they indicated
the wide range of healthcare topics and challenges that
will need to be addressed in the near future [13,14].
Clearly, reducing the socio-economic burden of cancer
on global healthcare systems is a complex and multifa-
ceted challenge [15,16]. Beyond the strategies of targeted
therapies and pharmaco-genomic analyses (discussed
below), other factors must be considered, such as pre-
ventative schemes addressing lifestyle-based risk factors
(obesity, inactivity, smoking, and alcohol misuse). More-
over, as lower-income nations are disproportionately
affected by cancer (as an NCD), there are also wider eth-
ical issues in reducing the ensuing healthcare inequal-
ities that will be presented.
Cancer and gender
Life-long risk factors for cancer development is in-
fluenced by gender-related factors such as different per-
ception to healthy diets, gender differences in lifestyle,
susceptibility to different infectious agents, hormonal
levels, different metabolism rates, and the use of differ-
ent medications, exemplified by the increased risk of
breast cancer in women using contraceptive pills and
hormone replacement therapy.
Of interest, there are also differences in bioavailability of
drugs in females and males due to gender-specific varia-
tions in expression and genotype distribution of various
drug-metabolizing enzymes (DME) [17]. Significant gen-
der differences were reported in the occurrence of adverse
effects of non-steroidal anti-inflammatory drug diclofenac
(DCF) with increased risk in males for liver fibrosis and
hepatocellular carcinoma [18] and adverse effects on the
cancer chemotherapeutic drug, ifosfamide, associated with
a more rapid CYP3A4-catalysis, suggesting a higher sus-
ceptibility to neurotoxic side effects in women [19]. In
addition to gender-associated genotypic differences in
DME that increase risk to cancer development and predis-
pose individuals to drug-related side effects, expression
and activity of DMEs are also under the effect of dietary
factors [20], exposure to drugs [21], disease states [22],
pregnancy [23], and endogenous hormonal factors [24].
There is a significant difference in these factors between
males and females [25,26].
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exemplified by the regulation of the cytochrome P450
oxidase CYP27A1 activity and expression in the pres-
ence of estrogen [24]. CYP27A1 converts cholesterol to
its primary metabolite 27-hydroxycholesterol (27HC),
which increased ER-dependent growth in breast cancer
mouse models. Hence, interference with the metabolism
of cholesterol and lowering circulating cholesterol re-
duces the risk to develop breast cancers and enhance re-
sponse to hormone therapy [27].
Implementation of screening programs
Screening programs aim to identify individuals with a gen-
etic predisposition to cancer eligible for preventive mea-
sures, to recruit patients at an early stage of the disease to
allow effective treatments, and to identify individuals who
harbor high-risk agents for cancer initiation eligible for
treatment to eliminate the high risk factor, such as viruses.
Various markers are used today as part of the public
health initiatives to ensure (1) early diagnosis, exemplified
by PSA testing; (2) characterization of monogenic syn-
dromes that lead to cancer initiation, such as the BRCA1/
2 [28] and hMSH2 [29] genes contributing significantly to
an increased risk of breast and hereditary nonpolyposis
colorectal cancer (HNPCC), respectively, and (3) genetic
subtyping of human papillomaviruses (HPVs) to identify
high-risk individuals to develop cervical cancer. Tech-
niques to identify tumor-related markers using noninva-
sive sampling, will provide the proper tools for screening
programs [30,31]. Screening population at risk requires in
depth cost-benefit analysis to justify the healthcare costs.
Mass screening of the entire female population for BRCA1
mutations is not justified within a public healthcare system
due to the low incidence of the mutations in a population,
as opposed to the high penetrance of BRCA1 mutants in
individuals with family history. Hence, screening of famil-
ial cases is more than justified when the right tools and in-
frastructure to implement programs are utilized.
Risk factors predisposing to cancer progression
Viruses and cancer risk
Increasing epidemiological evidence provides informa-
tion on infective etiology of specific cancers. Prevention
of infections is a healthcare measure to reduce the inci-
dence of human cancers worldwide. Various viruses are
now recognized to be a major risk factor in cancers, in-
cluding the sexually transmitted HPVs in cervical lesions
and cancers, hepatitis B virus in hepatocellular carcin-
oma, and Epstein-Barr virus associated with various
lymphoid malignancies. It is also recognized that retrovi-
ruses are a major contributor to the infective etiology of
childhood leukemia.
Infection of epithelial cells with HPV is a major risk
factor for cervical intraepithelial neoplasia (CIN) andcervical carcinoma [32]. In Europe, 328 million women
(age ≥15 years) are at risk to develop cervical cancer.
Cervical cancer ranks the fifth most frequent cancer
among women with 58,000 diagnosed annually [33]. The
early age of onset of cervical cancer ranks the disease
the second most common female cancer in women aged
15 to 44 years in Europe.
Because current vaccines against HPV 16 and 18 are
not designed to protect against other high-risk (HR)-
HPV genotypes [34], epidemiological studies within pop-
ulations are important to estimate the impact of the use
of vaccines on the healthcare system. HPV infections are
also associated with other anogenital cancers, head and
neck cancers, and other cancers, including the role of
HPV in the development of breast cancer [35].
Human papillomavirus-induced cervical precancerous
lesions
Today, it is known that in the development of HPV-
induced cervical dysplastic lesions, the key impact has a
specific cellular immune reactivity to HPV, especially the
Th1-type response of T helper cells, that develops by bal-
ancing various opposition groups of cytokine, in particular,
pro- and anti-inflammatory cytokines [36]. The import-
ance of the immune reactivity is confirmed by the fact that
patients with immunodeficiency states with suppressed
cellular immunity, such as AIDS, are extremely susceptible
to HPV-induced cancers. It is known that immune sup-
pression influenced oncoproteins E6 and E7 of HPV high-
risk oncogenic gene expression of interferon, interferon
genes, and IL-18 production as well as increased pro-
duction of immunosuppressive cytokines that inhibit the
development of T helper cells of Th1-type and the pro-
duction of interferon-γ and IL-2, play a key role in the
evolution of mechanisms against HPV immune factors
[36]. The presence of low-avidity IgG antibodies to HSV-1
and/or HSV-2 in the serum of patients with HPV-induced
cervix precancerous diseases does not depend on the re-
activation of HSV genome (genital herpes or generalized
herpetic infection), which might be an indication for treat-
ment as immunomodulators and antiviral (antiherpetic)
drugs.
Induction of oxidative stress promotes HPV-initiated
carcinogenesis. In inflammation, reactive oxygen species
(ROS) and nitric oxide (NO), generated by inflammatory
cells, play a key role in carcinogenesis. Thus, ROS can
induce the formation of 8-oxodG, an indicator of oxida-
tive DNA damage whereas NO can induce the formation
of 8-nitroguanine, a marker of nitrative DNA damage.
These factors are potentially mutagenic, which might ac-
count for the cancer-promoting effect of inflammation.
It is reported that high-risk HPV types promote indu-
cible NO synthase-dependent DNA damage, which leads
to dysplastic changes and carcinogenesis [37]. Whereas
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the abatement of oxidative stress, neutralizing this cellu-
lar disorder could minimize collateral damages associ-
ated with the transformation of biomolecules in the
cytosol. There were illustrated extensive interrelations
among virus action, cellular oxidative stress, gene dam-
age, multiple immune pathways and proteomic changes
in diabetes mellitus, cancer, and many chronic disorders
development, many of them were also related to HPV
infection [38].
Gut microbiota, inflammation and cancer
Metabolic disturbances are associated with a number of
diseases, including cancer development in lung, breast,
uterus and ovary, and others such as cardiovascular dis-
eases, violation of ovarian-menstrual cycle, local and sys-
temic immunity, and dyslipidemia. Cancer and coronary
heart disease are the most important disorders that
cause alarming mortality and morbidity in humans [39].
For many years, atherosclerosis and cancer were consid-
ered to have a completely unrelated pathogenesis and
disease progression pathway featuring separate thera-
peutic strategies. The various predictive and etiological
factors, biomarkers, and molecular pathways of disease
development and progression that are common to ath-
erosclerosis and cancer suggest that the two most com-
mon diseases worldwide are far more closely aligned
than previously believed. Both diseases share common
etiological factors: genetic predisposition, age, sex hor-
mones, cigarette smoking, high dietary fat intake, toxins,
and mutagens. The consequences of the abovemen-
tioned etiological factor actions are cell cycle deregula-
tion, oxidative stress, chronic inflammation, endothelial
dysfunction, dysregulation of apoptosis, and angiogen-
esis, DNA instability, and impaired DNA repair. In
addition to the aforementioned biological markers and
pathogenic factors common for atherosclerosis and can-
cer disease development, a number of additional genetic
pathways have been implicated in the progression of
both diseases. The TGF-ß signaling pathway, other growth
factors, cell adhesion molecules, the Wnt-ß-catenin signal-
ing pathway, excess matrix digestion associated with
matrix metalloproteases, and NF-kB signaling pathway
represent other common molecular progression pathways
shared by both diseases. Shared disease progression in ath-
erosclerosis and cancer is the emergence of similar novel
approaches to therapy [40,41].
Signals from the intestinal microbiota are important
for normal host physiology; alteration of the microbiota
(dysbiosis) is associated with multiple disease states [42].
Identification of components of the microbiota and elu-
cidation of the molecular mechanisms of their action to
induce pathological changes or exert beneficial, disease-
protective activities could aid in our ability to influencethe composition of the microbiota and to find bacterial
strains and components (e.g., probiotics and prebiotics)
whose administration might aid in disease prevention and
treatment. Examination of the role of the microbiota in
human illnesses using animal models of human diseases
reared in defined conditions could allow insight into the
unusual complexity of the mechanisms involved in the ini-
tiation and maintenance of chronic diseases [43].
Current knowledge shows that the colonic microflora
is involved in the etiology of colorectal cancer. Intestinal
bacteria can produce substances from dietary compo-
nents that have genotoxic, carcinogenic, and tumor-
promoting activities. The bacterial groups (lactobacilli
and bifidobacteria) have much lower activities of en-
zymes that can generate carcinogens than do other gut
microflora components such as clostridia and bacter-
oides. The balance of microbial types in the gut is very
important and beneficial modulation of the intestinal
microflora could decrease the colorectal cancer risk [44].
It might be hypothesized that not only common ap-
proaches to therapy but also common preventive strat-
egies could be efficacious in both diseases. Probiotics
and substances of natural origin can represent such a
preventive approach.
Cancer predisposing syndromes
Inherited mutations in the genes phosphatase and tensin
(PTEN), p53, STK11/LKB1, hMSH2, RB1, MEN1 and VHL
give rise to predisposing syndromes, namely Cowden’s dis-
ease [45], Li-Fraumeni syndrome [46], Peutz-Jeghers syn-
drome [47], Lynch syndrome [48], retinoblastoma [49],
Wermer syndrome [50], and von Hipple-Lindau syndrome
[51], respectively. The estimated lifetime risk (70 years) for
(1) the development of breast cancer is 85.2% (71.4%–
99.1%) in individuals with Cowden syndrome and 45%
(27%–68%) in individuals with Peutz-Jeghers syndrome; (2)
the development of colorectal cancer is 48% (30%–77%) in
individuals with mutations in hMSH2, one of the genes in-
volved in Lynch syndrome, and 9% (3.8%–14.1%) in indi-
viduals with Cowden syndrome.
These inherited susceptibility genes have a low fre-
quency, with a high penetrance. Hence, these genes are
candidates for a testing program in specialized clinics to
screen family members of patients, identify risk, and ini-
tiate preventive monitoring, or discuss possible clinical
solutions to reduce the risk significantly [52]. Screening
programs for cancer susceptibility genes is exemplified
by screening of BRCA1/2 in families of breast cancer.
Understanding cancer at a molecular level
A personalized therapeutic plan is important for effect-
ive individual patient care. Thus, many clinicians and
basic scientists have sought to develop better diagnostic
tests to predict patients’ responses to chemo, radiation,
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eity and individual differences make it difficult to develop
effective cancer treatments [55,56]. Our understanding of
the molecular mechanisms of cancer has to progress fur-
ther to accelerate the development not only of more thera-
peutic drugs but also more sophisticated diagnostics for
personalized treatment [57,58]. Finally, personalized treat-
ment will be practical in the near future, with optimized
prescriptions to optimize the right drug to the right pa-
tient at the right dose at the right time for the right
duration.
Here, we briefly review the characteristics of cancers
at various molecular levels, at the gene, protein, and me-
tabolite level, as well as the current status of molecular
cancer diagnostics and preventative markers.
At the gene level
Genetic aberrations play a significant role in cancer devel-
opment [59]. Alterations in genomic sequences occur in
the initial stage of carcinogenesis. Thus, the discovery of
genetic alterations that occur in cancer development has
been used to detect cancers [60-62]. Such signature
changes include single-nucleotide polymorphisms (SNPs),
the number of gene copies, microsatellites, and promoter
methylation status.
SNPs
SNPs are the most common genetic variations and occur
approximately every 1,000–2,000 bases in the human gen-
ome [63,64]. Most human sequence variation is attribut-
able to SNPs, with the rest due to insertions or deletions
of one or more bases, repeat-length polymorphisms, and
rearrangements. When SNPs are in important genes, al-
lelic imbalances are induced and, therefore, carcinogenesis
might be initiated. SNPs are a promising tool to identify
patterns of cancer risk. SNPs are detected by the profiling
of transcription patterns. The frequency of shared poly-
morphisms might provide information on relative rates of
mutation, recombination, and gene conversion [65]. For
example, it has been known that protein phosphatases
(PPs) might function as tumor suppressors by antagoniz-
ing protein kinases [66]. It was found that genetic muta-
tions (two missense mutations) in the regulatory subunit 3
of the PP1 (PPP1R3) gene function as a tumor suppressor
in human carcinogenesis, wherein five SNPs were iden-
tified in two colorectal carcinomas and ovarian carcin-
oma [67]. Hence, variable genetic polymorphisms in the
PPP1R3 gene can be involved in human carcinogenesis.
To assess the susceptibility of individuals with genetic
variants to cancer, cumulative evaluation of all SNPs
within an individual is required. For example, common
variants on human chromosome 8q24 were identified to
be associated with prostate cancer susceptibility [68]. A
genome-wide association study of SNPs in prostatecancer patients showed rs6983267 in the centromeric
locus association with prostate cancer [69]. Additionally,
another study reported that a genome-wide association
scan of tagSNPs in colorectal cancer patients found that
common, low-penetrance susceptibility alleles at 8q24.21
predispose to colorectal cancer development [70]. Fur-
thermore, the most representative colorectal adenoma-
associated SNP was rs6983267, also at 8q24.21, which
causes enhanced Wnt signaling [71].
Accumulated SNP data can accelerate the use of SNPs
for detection of cancers. Analysis of SNPs has been
performed by hybridization of DNA probes or high-
throughput technologies to identify cancer-associated
polymorphic alleles [65,72,73].
Aberrant copy number
Differences in gene-copy number are another highly sig-
nificant type of genetic variation. All cells have two cop-
ies of autosomal genes. When a mutation occurs in one
allele of a tumor-suppressor gene, loss of heterozygosity
(LOH) can lead to carcinogenesis. Because variation in
gene copy number can affect the level of protein expres-
sion, copy-number variation is one of the most import-
ant determinants of individual traits between patients,
including differences in susceptibility to various cancers.
Proofreading and DNA mismatch repair (MMR) are
integral parts of the maintenance of high-fidelity DNA
replication [74]. Defects in MMR increase overall genetic
alterations, which cause cancer incidence. A somatic
P286R substitution in the conserved exonuclease I do-
main of DNA polymerase ε was found in 52 sporadic
colorectal tumor specimens. LOH of the variant allele
(P286R mutation) functioned as a strong factor to ele-
vate cancer incidence [75].
LOH can be detected by various approaches, based on
PCR, in most pre-neoplastic lesions and primary tumors.
Whole-genome sequencing has the potential to capture
targeted coding sequences with high sensitivity and speci-
ficity for the detection of homozygous and heterozygous
variants [76]. Thus, whole-exome sequencing might have
clinical utility in the discovery of cancer-associated LOH
and in making clinical diagnoses [77].
Microsatellite alterations
Microsatellite instability (MIN) involves changes in thou-
sands of microsatellite sequences scattered throughout the
genome. Microsatellites are simple sequence repeats (SSRs)
or simple/short tandem repeats in which the repeats con-
tain 1–13 base pairs [78]. SSRs affect the genes with which
they are associated. Thus, changes in the numbers of SSRs
can affect gene regulation, transcription, and protein
function [79]. For example, one report demonstrated
that microsatellite instability at (CA)n repeats on hu-
man chromosomes 5q, 15q, 17p, and 18q correlated
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patient survival [80].
Instability at the nucleotide level is the result of mis-
takes in DNA repair, which can lead to tumor progres-
sion and tumor heterogeneity. In HNPCC, mutations in
the hMSH6 gene are caused by post-replicative mis-
match repair. This mutation has been studied with ana-
lysis of the pattern of the polymorphisms, which could
allow better diagnosis of HNPCC [81]. Additionally, the
alteration of microsatellite loci causes changes in the
length of repeats during replication as a result of dysreg-
ulation in proofreading by exonuclease and MMR en-
zyme reactions [81]. Moreover, somatic mutations of
microsatellites have also been observed in cancers of the
gastrointestinal tract [82], lung, soft tissue, breast [83],
and bladder [84].
Promoter hypermethylation
DNA methylation is an important factor in many pro-
cesses, including DNA repair, genome stability, and the
regulation of chromatin structure [85,86]. DNA methyla-
tion refers to the covalent addition of a methyl group at
the 5’-carbon of the cytosine ring, to form 5’-methylcy-
tosine [87]. These methyl groups effectively inhibit tran-
scription. “CpG islands” are local regions where CpG
sites are found more frequently in small stretches of
DNA. Gene silencing in cancer is associated with pro-
moter hypermethylation [88].
DNA hypermethylation has been observed in various
cancers. For example, BRCA1 activity is markedly
decreased in invasive breast tumors. In breast cancer,
however, hypermethylation is often found in BRCA1
[89]. In hematopoietic malignancies, DNA hypermethy-
lation often silences tumor suppressor genes that encode
cell adhesion molecules and growth-regulatory proteins
[90]. Methylation of the MLH1 MMR gene has also been
observed in colorectal cancer [91]. Silencing of the von
Hippel-Lindau (VHL) tumor-suppressor gene occurs by
DNA methylation in renal carcinoma, similar to BRCA1
in early breast cancer [90,92]. Moreover, methylation in
the promoter of the O6-methylguanine methyltransferase
(MGMT) gene is known as a clinical prognostic factor re-
garding the action of alkylating agents in gliomas [93].
MGMT is involved in DNA repair in colon cancer, lymph-
oma, non-small cell lung cancer, and brain tumors. Thus,
its inactivation by promoter methylation may be import-
ant in the expected utility of targeted therapeutics [94].
Tremendous advances in high-throughput screening and
detection, such as DNA microarrays and multiplexed as-
says, have allowed the identification of novel biomarkers.
DNA microarrays offer rapid surveillance of expression pat-
terns of tens of thousands of genes in a single experiment.
DNA microarrays, as a tool for profiling transcription pat-
terns, can analyze hundreds or thousands of genes in asingle assay [95] and replace differential PCR-based ap-
proaches in some applications. Gene expression profiles
can indicate transcriptional variation between healthy and
cancerous cells. The use of this technique generally relies
on clustering analysis of several genes that differentiate can-
cer versus normal profiles rather a single gene.
Messenger RNA level
Messenger RNAs (mRNAs) and microRNAs (miRNAs)
have been a focus as key components in understanding
cancer and are known to contribute to the regulation
of cancer-signaling pathways [96]. Dysregulation at the
mRNA level occurs in various cancers because the mo-
lecular processes of mRNA are complex and multilayered.
The most common method to identify and quantify
mRNA levels from patients’ samples is reverse-
transcription PCR (RT-PCR) [97]. For example, carci-
noembryonic antigen (CEA) levels in colorectal cancer can
be detected by RT-PCR. Increased CEA mRNA isolated
from RNA in serum might indicate micrometastatic bone
disease in patients with CEA-expressing carcinomas, using
CEA-specific PCR [98]. Prostate-specific antigen (PSA)
mRNA can also be detected and quantified with molecular
assays that detect PSA-synthesizing cells in the peripheral
circulation of patients with prostate cancer [99].
Changes in mRNA transcript stability have also been im-
plicated in cancer progression. For example, destabilization
of mRNAs by a protein that binds structural elements of
mRNAs can regulate cancer progression [100].
Quantitative mRNA analysis can also be used to detect
multiple biomarkers in the serum of patients with breast
cancer [101]. In colon cancer, levels of mRNA encoding
dihydropyrimidine dehydrogenase, thymidylate synthase,
and thymidine phosphorylase have allowed predictions
of responses to 5-fluorouracil therapy [102].
MicroRNA
Isolation and preparation of total RNA from tissues and/or
body fluids such as blood or urine make it possible to glo-
bally analyze RNA profiles, including small RNAs, such as
miRNAs. Recently, some reviews have focused on the role
that deregulated mRNA translational control in eukaryotic
cells and mammalian systems might play in carcinogenesis
[103,104]. miRNAs are small non-coding RNAs involved
in virtually all functional aspects of eukaryotic cells, in-
cluding embryonic development, cell differentiation and
proliferation, cell death, energy metabolism, and antiviral
defense. Dysregulation of miRNAs is often associated with
various cancers because the control of miRNA levels is im-
portant for normal functioning in cells [105,106]. miRNAs
serve as key regulators of gene expression and affect cellu-
lar gene expression networks markedly [107,108]. It has
also been shown that changes in the expression of miRNA
might contribute to carcinogenesis.
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cancers to be classified according to the lineage and the
state of the cancers. For example, miRNA profiling studies
showed that distinct patterns of miRNA characterize
different hematopoietic differentiation stages in acute leu-
kemia samples: the BCR-ABL, TEL-AML1 -(acute myeloid
leukemia 1 also known as runt-related transcription factor
1 (RUNX1)) and mixed lineage leukemia (MLL) rearrange-
ments could be distinguished [109,110]. miRNA includes
onco-miRNAs and tumor-suppressor-miRNAs. For ex-
ample, miR-21 is aberrantly expressed in glioblastomas,
and its overexpression might induce carcinogenesis by
blocking expression of critical apoptosis-related genes
[111,112]. In the human B-cell line P493-6, overexpressing
MYC, the miR-17-92 locus has tumor suppressor activity.
Its expression curbs MYC-involved proliferation by inhi-
biting the expression of E2F1 [113].
Because the dysregulated expression of miRNA genes
has been attributed to carcinogenesis controlled by mul-
tiple oncogenes or tumor-suppressor genes, understand-
ing miRNAs will be important to understanding the
cancer too and provide crucial clues for the development
of future miRNA-based therapies [114]. Advanced gen-
omic technologies have now determined that at least
90% of the genome is actively transcribed [115,116].
At the protein level
Dysregulation in protein expression, post-translational
modifications (PTMs), protein-protein interactions, as well
as dysfunction in specific protein activity and inappropriate
localization of proteins can all occur during carcinogenesis
[117]. Abnormalities in the modification of proteins may
be important for the signaling, metabolic, or structural
properties of the cell and cause disorders in biogenesis,
protein aggregation, cell metabolism, or signaling. Under-
standing such post-translation events is possible through
recently developed proteomics-based tools.
Dysfunction in enzyme activity
Dysfunction in the catalytic activity of certain enzymes
can lead to pathogenic alterations in the pattern of gene
transcription within a particular cell type. For example,
changes in protein methyltransferase (PMT) activity play
critical roles in carcinogenesis [118]. Deregulation of
PMT activity, affected by genetic alterations, can reduce
levels of transcription of specific tumor suppressor genes
or induce those of specific oncogenes [118,119]. Thus,
several PMT enzymes might be targets in personalized
treatment such as by using small-molecule inhibitors of
PMTs (PMTis), including DOT1L and EZH2 [120].
Mislocalization of proteins
The appropriate localization of proteins is a fundamental
requirement for them to exert their expected function.Protein mislocalization can lead to their inactivation (loss
of function) or overexpression (gain of function) [121]. For
example, a shift in BRCA1 cellular localization often oc-
curs in human breast cancers of differentiated grade and
patients with BRCA1 mutations [122-124]. Blockage of the
nuclear localization of full-length BRCA1 was observed
when a mutation was found in the carboxyl-terminal do-
main of the BRCA1 protein [125,126]. Thus, gene muta-
tions and alternative splicing in the BRCA1 gene might
have effects on the nuclear import and distribution of the
BRCA1 protein, which might play a role in breast cancer
development [127].
Protein kinases
Kinases have critical roles in phosphorylating molecules
in signaling pathways. Deregulation of kinases can turn
on or change signals governing proliferation, migration,
survival, and differentiation. Oncogenic kinase proteins
participate in various cellular signaling steps in malig-
nant cells [128].
Tyrosine kinase signaling is a representative signaling
pathway involved in cancer mechanisms. Tyrosine kinases,
as a class of enzymes, are key regulators of many important
cellular regulatory processes, such as cell growth, differen-
tiation, cell survival, cell migration, and cell-cycle control,
that can contribute to cancer development and progression
[129]. Tyrosine kinases include receptor protein kinases—
e.g., epidermal growth factor receptor (EGFR) (ErbB/HER)
family members, vascular endothelial growth factor recep-
tors (VEGFR), and platelet-derived growth factor receptors
(PDGFR) (α and β)—and non-receptor protein kinases,
such as BCR-ABL and KIT [130]. Their mutations contrib-
ute to deregulation of tyrosine phosphorylation, which can
play an important role in oncogenesis. In non-small cell
lung cancer, somatic mutations of EGFR2 have been docu-
mented [131]. Also, somatic mutations of EGFR2 and
EGFR3 have been observed in human bladder and cervical
carcinomas [132,133]. Aberrant expression of ErbB recep-
tor also causes the development of epithelial cancers [134].
Other proteins
The most well-known protein-based marker is likely to
be PSA, which is found at high levels in the serum of pa-
tients with prostate cancer [135]. Cancer antigen (CA)
125, another older marker, is widely used to detect ovar-
ian cancer [136]. Furthermore, upregulated fecal tumor
M2-protein kinase (M2-PK) has been observed in the
stool of colorectal cancer (CRC) patients [137,138].
Recent advances, especially in mass spectrometry, have
enabled high-content quantitative information about pa-
tient samples and facilitated the analysis and functional
characterization of protein complexes and protein path-
ways [139,140]. Further genomics and proteomics tech-
nologies in development have further promise to identify
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cancer development/progression and to enhance person-
alized medicine.
Metabolites
Metabolites are measured systemically to assess the dy-
namics of changes in metabolites and the metabolome in
a cell or tissues, as associated with various physiological
and pathological states in a patient [141]. Analysis of me-
tabolites can allow a global understanding of discrepancies
in biological systems in individuals. Moreover, recently
developed high-throughput technologies can provide re-
searchers with a deeper understanding of cancer-specific
metabolism and facilitate multidisciplinary approaches to
the study of cancers [142].
The metabolites used as cancer markers can be classi-
fied with their associated biochemical pathways. Many
of the metabolic disturbances observed are due to the
need to support the cancer’s high cell growth and prolif-
eration, such as changes in glycolysis, the tricarboxylic
acid (TCA) cycle, transcription and translation, and pur-
ine and pyrimidine metabolism.
Glycolysis
Because of the Warburg effect, glycolytic activity is in-
creased in cancer cells. Thus, adenosine triphosphate
(ATP) is produced in large amounts via the glycolysis path-
way in most cancers [143]. Additionally, the expression of
Na+-dependent glucose transporters (GLUT) is increased
when glycolytic enzymes, such as phosphoglycerate kinase
1 and alpha-enolase are activated [144,145]. The decrease
in glucose, as a result of rapid cancer cell proliferation, can
be measured to diagnose hepatocellular carcinoma [146],
renal cell carcinoma [147], and cervical cancer [148]. To-
gether with changes in glucose, elevated levels of pyruvate
and lactate can also serve as tools to differentiate normal
tissue from hepatocellular carcinoma [149], colorectal can-
cer [150], stomach cancer [151], and oral cancer [152].
Tricarboxylic acid cycle
Alterations in the TCA cycle, such as lower levels of cit-
rate and elevated levels of fumarate, malate, and succinate,
are found in various cancers. For example, functional im-
pairment of TCA cycle results from mutation of fumarase
gene in leiomyoma [153].
In gliomas, mutations in the enzyme cytosolic isocitrate
dehydrogenase 1 (IDH1) can cause loss of the enzyme’s
ability to catalyze the NADPH-dependent reduction of α-
ketoglutarate to 2-hydroxyglutarate (2HG). Overaccumu-
lation of 2HG has been detected in gliomas [154].
Pyruvate metabolism
When levels of pyruvate oxidation become lower and gly-
colysis is activated, levels of lactate and alanine becomeelevated. This metabolic phenotype can provide a selective
growth advantage for cancers [155,156]. Elevation of
pyruvate contributes to the formation of hypoxic condi-
tions in cancer cells and might ultimately induce cancer
development and progression [156]. Additionally, in sev-
eral gliomas, markedly increased alanine levels have been
detected [157].
Other metabolic markers
Cancer metabolic markers related to brain and pros-
tate cancers, such as N-acetyl-aspartate (NAA) and
sarcosine, respectively, have also been identified and
assessed [99,158,159].
We have briefly reviewed the molecular traits and mech-
anisms of cancer at each molecular level. In the initial
stages of cancer development, changes in SNPs, the num-
ber of gene copies, microsatellites, and promoter methyla-
tion have been shown to be major events in carcinogenesis.
With respect to the expression of many genes, genetic al-
terations at the RNA level have also been regarded as hall-
marks of cancers. miRNAs have received much attention
because of their role to induce translational inhibition by
silencing targeted mRNAs related to cancer metabolism.
Furthermore, cancer-specific features at the protein level
involve altered protein expression and protein-protein in-
teractions, modifications of protein structure and enzyme
activity, and perturbations of cancer-related pathways and
localization during carcinogenesis. Metabolites have re-
cently been highlighted as biomolecules that indicate as-
pects of cancer metabolism, such as changes in glycolysis,
as well as provide significant information on the expression
of cancer phenotypes.
Although considerable knowledge about the molecular
bases of cancer has been accumulated thus far, we still
have many unsolved problems in cancer treatment. To
increase our understanding of cancer and to develop
truly personalized medicine, further advances in high-
throughput “omics” technologies are needed. These
technologies will allow global interpretation of discrep-
ancies in the biological systems of individuals and will
facilitate multidisciplinary approaches to personalized
medicine in the near future.
Current predictive markers
Colon cancer
CEA levels have been commonly used in clinical prac-
tice as part of the follow-up after curative resection for
CRC [160-162].
5-Flurouracil (5-FU), an antimetabolite, is the mainstay
of all current standard CRC chemotherapy regimens. Defi-
ciency in dihydropyridimine dehydrogenase (DPD) has
been associated with increased 5-FU toxicity through re-
duced metabolism to result in accumulation of 5-FU and,
hence, more serious and life-threatening side effects
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locus) can predict the accuracy of screening CRC patients
before administering 5-FU [165].
Evaluations of the benefits of adjuvant 5-FU chemo-
therapy in mismatch repair-deficient and mismatch
repair-proficient patients have been made. For mismatch
repair-deficient patients, there was no statistically signifi-
cant difference in relapse-free survival (RFS) or overall
survival (OS) regardless of whether patients received 5-
FU-based chemotherapy [166]. Also, there was no sig-
nificant effect on survival or disease-free survival (DFS)
of adjuvant 5-FU chemotherapy in 545 mismatch repair-
deficient patients [167,168]. However, recently, CRC
with a defective mismatch repair system did not respond
to adjuvant 5-FU chemotherapy [169].
A mutant Ki-ras2 Kirsten rat sarcoma viral oncogene
homologue gene (KRAS) accounted for ~ one-third of
patients who did not respond to anti-EGFR therapy.
Therefore, additional biomarkers for the efficacy of
EGFR therapy are required [170]. Because B-RAF is the
major effector of KRAS, a B-RAF mutation might well
be useful to predict the response to anti-EGFR therapy
for cancers in patients with wild-type KRAS, as well as
analysis of the KRAS mutation [171].
KRAS remains the only validated predictive marker
for anti-EGFR monoclonal antibody therapies (such as
cetuximab or panitumumab) for CRC. Among the clin-
ical studies that report positive outcomes, the CRYSTAL,
OPUS, and PRIME trials were early representative trials
with clinical outcomes.
Cetuximab Combined with Irinotecan in First-line
Therapy for Metastatic Colorectal Cancer (CRYSTAL)
was performed as a multicenter phase 3 trial [172].
When treated with irinotecan, fluorouracil, and leu-
covorin (FOLFIRI) plus cetuximab, there was a lower
metastatic risk of metastatic CRC (mCRC) than with
treatment with FOLFIRI alone. A limited efficacy of
cetuximab was seen in KRAS wild-type tumors.
The Oxaliplatin and Cetuximab in First-Line Treatment
of Metastatic Colorectal Cancer (OPUS) trials compared
treatments of oxaliplatin/5-fluorouracil/folinic acid (FOL-
FOX-4) plus cetuximab vs FOLFOX-4 alone. Administra-
tion of cetuximab in combination with FOLFOX-4 in
KRAS wild-type mCRC improved progression-free sur-
vival (PFS), response rate (RR), and overall response rate
(ORR) [173].
The Panitumumab Randomized Trial in Combin-
ation with Chemotherapy for Metastatic Colorectal
Cancer to Determine Efficacy (PRIME) examined the
efficacy and safety of panitumumab plus infusional
FOLFOX4 vs FOLFOX4 alone as an initial treatment
for mCRC. Panitumumab-FOLFOX4 treatment signifi-
cantly improved the PFS in patients with KRAS wild-
type tumors [174]. In short, the KRAS mutation statusinfluenced outcomes and was an effective predictive
biomarker in CRC.
In initial studies, the KRAS mutation in codons 12 and
13 of exon 2 were analyzed to predict the outcomes of
anti-EGFR monoclonal therapies [175,176]. Recently, be-
cause mutations of RAS have been established as predict-
ive factors for anti-EGFR monoclonal antibody treatment,
the treatment has also been more effective in patients with
all RAS wild-type tumors rather than just those with a
RAS mutation [177]. Moreover, in the American Society
of Clinical Oncology (ASCO) 2014, one clinical study re-
ported that mutations in RAS genes (KRAS/NRAS exons
2,3, and 4) predicted a lack of response to panitumumab
plus FOLFIRI therapy for mCRC [178]. The 2014 National
Comprehensive Cancer Network (NCCN) guidelines ex-
panded the extent of the therapeutic standards for mCRC
from KRAS mutations to all RAS mutational analyses, and
the clinical use of EGFR-directed monoclonal antibodies
cetuximab and panitumumab were allowed only in pa-
tients with wild-type RAS [179].
BRAF is one of the most common negative prognostic
markers validated to date even though it is unclear that
BRAF could play a role in the predictive marker in anti-
EGFR therapy. It is a poor prognostic marker not only
for the metastatic stage but also for stages II and III. For
example, wild-type BRAF in mCRC appeared to show
good PFS and OS outcomes in response to panitumu-
mab and cetuximab, respectively [180]. Furthermore, in
the MRC COIN trial, patients with advanced CRC who
had a mutated BRAF showed a poor prognosis in re-
sponse to the addition of cetuximab to oxaliplatin-based
first-line combination chemotherapies [181]. In cetuxi-
mab plus FOLFIRI as a first-line treatment for mCRC,
the BRAF tumor mutation was a strong indicator of a
poor prognosis [182].
Gastric cancer
There are fewer effective targeted therapies for the clinical
treatment of gastric cancer than there are for other can-
cers [183]. Trastuzumab (a recombinant monoclonal anti-
body against human epidermal growth factor receptor 2
(HER2)) was reported as a successful HER2-targeted ther-
apy as a first-line treatment for HER2-positive advanced
gastric or gastro-esophageal junction cancers [184].
In gastric cancer, HER2 is currently the only validated
predictive marker for HER2-targeted agents, with other
markers still to be validated [185]. Although amplification
of MET is a good candidate as a predictive marker, further
verification of its predictive value is needed. Immunohisto-
chemistry of EGFR could not predict the clinical responses
to cetuximab or EGFR tyrosine kinase inhibitors (TKIs)
[186,187]. Although a mammalian target of rapamycin
(mTOR) inhibitor could not improve the OS in a phase III
trial (GRANITE-1), multiple phosphorylation sites of S6
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improved disease control [188]. However, these still re-
main to be validated. Moreover, cisplatin and fluorouracil
improved the PFS in low expressions of EGFR, FGFR2,
and MYC [189].
Breast cancer
Great efforts have been made at the transcriptome level
to discern which ER-positive early breast cancer patients
would truly benefit from additional chemotherapy and
who could be spared from excessive treatment and side
effects [190]. Traditional classification systems of bio-
logical characteristics, hormone receptors (estrogen re-
ceptor (ER) and progesterone receptor (PR)) and HER2
(c-erbB2) status, might have limitations for patient-
tailored treatment strategies.
The expression of the ER is the most important bio-
marker in breast cancer because it provides an index of
sensitivity to endocrine treatments. Multiple clinical
studies have demonstrated that ER-negative breast can-
cer patients are more likely to achieve a pathological
complete response (pCR) with neoadjuvant chemother-
apy, as compared to ER-positive patients, with pCR rates
reported of 7%–8% vs 21%–33%, respectively [191,192].
The expression of the PR is strongly dependent on the
presence of the ER. In rare cases of solely PR-expressing
patients, some limited benefits from tamoxifen have been
described; however, endocrine therapy is still widely rec-
ommended [193]. The Arimidex, Tamoxifen, Alone or in
Combination (ATAC) Trialists’ Group published a report
that suggest that patients with PR-negative breast cancer
would obtain substantially greater benefits from anastro-
zole than from tamoxifen, as compared with PR-positive
patients [194].
The HER2 oncogene was initially used as an indicator of
patient prognosis. In cases of overexpression of HER2
(HER2-positive), breast cancer patients were more likely
to suffer from relapses and tended to have a shorter OS.
Through the development of the monoclonal antibody
trastuzumab, which is targeted at HER2, the amplification
status of HER2 became a highly predictive biomarker
[195,196]. Recent studies also describe an association of
HER2 amplification with benefits from adjuvant chemo-
therapies [197-199] as well as from combined chemother-
apy in metastatic breast cancer [200-203].
Measurement of Ki67 has the potential to radically
change the assessment of available prognostic markers.
Findings from our group indicated that post-neoadjuvant
chemotherapy measurement of Ki67 was a strong pre-
dictor for RFS and OS [204]. The role of cyclin E in the
cell cycle suggests that increased levels might alter re-
sponses to chemotherapy and endocrine therapy. Altered
levels of cyclin E increased the sensitivity of breast cancer
cells to the effects of cisplatin and paclitaxel [205].ERb mRNA levels were also used in the evaluation of
patient prognoses. The availability of specific antibodies
enabled ERb protein levels to be suggestive of a good
prognosis, prolonged DFS, and a response to tamoxifen
[206,207]. However, HER2-positive cancers, which showed
amplification and overexpression of the ERBB2 gene, did
not express hormone receptors and thus represented a
poor prognosis [208-210].
HER-2/neu has been used in the clinical treatment of
breast cancer since it gained FDA approval after immuno-
histochemistry testing. The American Society of Clinical
Oncology and the College of American Pathologists
(ASCO/CAP) also recommended use of the HER-2/neu
test to select patients suitable for herceptin therapy [211].
Additionally, CA27.29, and CA15-3 are the most widely
used serum biomarkers that are highly associated with
breast cancer and are derived from the MUC1 gene [212].
Testing of the clinical activity of trastuzumab in women
with HER2-positive breast cancer demonstrated that a sin-
gle year of adjuvant chemotherapy treatment with trastu-
zumab improved the DFS [197]. Adjuvant chemotherapy
(paclitaxel after doxorubicin and cyclophosphamide) with
concurrent trastuzumab administrated to women after
surgical resection of HER2-positive breast cancers had im-
proved outcomes compared with adjuvant chemotherapy
alone [198]. Although a nonanthracycline chemotherapy
regimen combined with trastuzumab was related to car-
diac toxicity, trastuzumab improved the survival rate in
the adjuvant treatment of HER2-positive breast cancer.
Therefore, for women with HER2-positive breast cancer,
treatment with adjuvant trastuzumab improved the DFS
and OS, and trastuzumab was recommended as an effect-
ive alternative to anthracycline-based regimens [199].
In HER2-overexpressed metastatic breast cancers, ini-
tial chemotherapy treatment with trastuzumab resulted
in a longer time to disease progression, a longer duration
of response, a lower rate of death at 1 year, longer sur-
vival, and a 20% reduction in the risk of death [200].
A randomized phase III study (TAnDEM) compared
the clinical outcomes of anastrozol combined with tras-
tuzumab to those of anastrozole alone in postmeno-
pausal women with HER2/hormone receptor-positive
metastatic breast cancer (MBC). Although there were
more adverse and serious adverse events in the combin-
ation treatment of trastuzumab plus anastrozole than in
the treatment of anastrozole alone, treatment of trastu-
zumab plus anastrozole significantly improved PFS, time
to progression (TTP), clinic benefit rates (CBR), and
ORR [213].
Cross-talk between the EGFR and the hormone recep-
tor (HR) in HR-positive MBC results in resistance to
conventional endocrine therapies [214]. To overcome re-
sistance, lapatinib (a dual tyrosine kinase inhibitor) that
blocks EGFR and HER2 was administered together with
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PFS and clinical benefits in patients with HR/HER2 co-
expressed MBC [215].
Trastuzumab emtansine (T-DM1) is an anticancer drug
that has the anticancer effects of HER2-targeted trastu-
zumab and the cytotoxic activity of the microtubule-
inhibitory agent DM1. Clinical effects were improved after
administration of T-DM1 and of lapatinib plus capecita-
bine, as compared to treatment with trastuzumab plus
taxane for patients with HER2-positive advanced breast
cancer. In the T-DM1 group, PFS and OS both increased,
and there was decreased toxicity [203].
Lung cancer
Cell cycle markers are some of the most powerful pre-
dictors of survival. In one study, multiple markers in 408
stage I patients were evaluated, and high Rb expression
was associated with an improved 5-year survival rate, al-
though the results did not achieve statistical significance
[216]. Up-regulation of the cyclin D1 proto-oncogene is
known to be important in the regulation of the cell cycle
pathway. In a study limited to stages I and II, cyclin D1
expression was associated with shorter survival and the
worst prognosis was observed in tumors with a combin-
ation of high cyclin D1 expression and loss of p16 ex-
pression [217].
Some mediators of apoptosis might be predictors of sur-
vival in lung cancer. For instance, as high expression of
apoptosis inhibitors, survivin is significantly favorable for
survival in patients with non-small-cell lung carcinoma
(NSCLC), and up-regulation of Fas might also indicate a
favorable prognosis in NSCLC with stage III disease
[218,219]. Single studies of TNFR-1, TNFR-2, and TNF-a
showed that these markers were also associated with im-
proved survival rates in NSCLC patients [219,220]. In a
study of 135 patients with stage I NSCLC, hypermethyla-
tion of the death-associated protein (DAP) kinase pro-
moter was found in 44% of the tumors and was a
significant independent factor that predicts poorer disease-
specific survival [221]. Several other studies suggested that
bcl-2 was an independent prognostic marker of improved
survival [222-224]. In one small study of advanced disease,
Bax expression was associated with improved median sur-
vival in stage IV NSCLC [225].
Other markers such as p53 and RAS have prognostic
and predictive relevance in adjuvant chemotherapies
(adjuvant cisplatin plus vinorelbine) in NSCLC. Protein
overexpression of p53 was a significant prognostic marker
of shortened survival as well as a predictive marker to in-
dicate greater survival benefits of adjuvant chemotherapy
in completely resected NSCLC patients [226]. Multifunc-
tional proteins such as p53 and RAS are critical to cell
cycle regulation, apoptosis, cell survival, gene transcrip-
tion, response to stress, and DNA repair. Four largestudies that were limited to stage I patients yielded con-
flicting results [216,227-229]. In the largest study, increased
p53 expression had no effect on the outcome [228].
For p53, most studies focused on bcl-2 as a second
marker. Two studies suggested that a combination of in-
creased p53 expression and decreased bcl-2 expression
indicated the poorest survival rates [230]. Similar results
were also seen in a combination of p53 and Rb expres-
sion [231,232]. The interrelationships between these pro-
teins in the cell cycle and the apoptotic pathways might
explain the potentially synergistic effect of p53 and bcl-2
or Rb.
The mutational status of KRAS could also be a strong
prognostic marker for adenocarcinoma of the lung. A
point-mutation in codon 12 of KRAS was evaluated with
RAS-specific DNA sequencing, which confirmed that
the presence of a KRAS point-mutation in lung cancer
indicated a poor prognosis and shorter DFS [233]. The
KRAS mutational status was also indicative of a reduc-
tion in the therapeutic efficacy of EGFR-TKIs; however,
it did not affect the chemotherapeutic efficacy. These re-
cent findings demonstrated that mutations in EGFR or
in KRAS affected the sensitivity to EGFR-TKIs, such as
erlotinib. In NSCLC, there was a greater likelihood of re-
sponse to chemotherapy when combined with erlotinib,
as compared to chemotherapy alone. However, patients
with KRAS-mutant NSCLC showed poorer clinical out-
comes when treated with erlotinib and chemotherapy
[234]. The presence of mutations in EGFR and KRAS
could be a strong predictor of resistance to EGFR-
targeted monoclonal antibodies.
In bronchioloalveolar carcinoma (BAC) and adenocar-
cinoma, a phase II trial to determine the efficacy of erlo-
tinib against BAC subtypes was performed. Erlotinib
proved active against BAC and adenocarcinomas and
mixed subtypes of BAC. Evaluation of EGFR and KRAS
mutations could predict the RR and PFS after erlotinib
administration, and histologically enriched subsets de-
rived from patients could help with clinical NSCLC trials
of the use of EGFR-directed therapies [235].
In the Biomarker-integrated Approaches of Targeted
Therapy for Lung Cancer Elimination (BATTLE) trial,
erlotinib, vandetanib, erlotinib plus bexarotene, or soraf-
enib, were randomly used to treat chemorefractory
NSCLC. For patients with mutant KRAS, treatment with
sorafenib showed some impressive benefits [235].
Clinical outcomes of responses to gefitinib (an EGFR
tyrosine kinase inhibitor) were higher in EGFR-mutated
patients with advanced NSCLC. In addition, in the
EGFR-mutated group, administration of gefitinib further
increased PFS and the acceptable toxicity, as compared
to standard chemotherapy [236,237].
Additional molecular markers might also be used to
indicate tumor status. PDGF expression in the stromal
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comes in NSCLC than tumor cell expression [238,239].
Basic fibroblast growth factor (bFGF) is released by
proteolytic enzymes from the extracellular matrix, after
which it increases the expression of other proteolytic
molecules. In a follow-up study, there was an associ-
ation between the presence of tumor-infiltrating mac-
rophages and tumor IL-8 expression that suggest a
mechanism for how macrophages adversely affected
outcomes in NSCLC [240].
Liver cancer
Potential prognostic markers in liver cancer include p53
mutations, the PTEN homologue, c-met, c-myc, p18,
p27, p57, serum VEGF, hypoxia-inducible factor-1 (HIF-
1)a, MMP-2, MMP-7, and MMP-12, as well as prolifera-
tion indices, telomerase activity and aneuploidy.
DNA mutation analysis is a useful technique to assess
p53 status. The majority of studies that investigate p53
mutations have found them to be associated with shorter
DFS and OS [241-245]. Positive expression of the PTEN
tumor suppressor gene has been identified as an inde-
pendent prognostic factor for decreased OS following re-
section for hepatocellular carcinoma (HCC) [246,247].
In HCC, c-met is commonly over-expressed and has
been associated with reduced OS in prognostic studies
[248,249]. Expression of c-myc was increased in those
patients who develop early recurrence post-hepatectomy
[250], potentially through overexpression of cancerous
inhibitor of protein phosphatase 2a (cip2a) [251].
Multivariate analyses have shown that Bcl-xL overex-
pression could independently predict decreased OS and
DFS [252]. Garcia et al. found that expression of the
pro-apoptotic protein Bax independently predicted in-
creased OS following resection of HCC [253].
Survivin is a member of the inhibitor of apoptosis pro-
tein (IAP) family of anti-apoptotic proteins. Patients with
tumors that express survivin mRNA suffered higher
rates of recurrence and poorer disease-specific survival
rates than those with tumors that did not express survi-
vin mRNA [254,255]. A high survivin/GADPH mRNA
ratio was shown to independently predict tumor recur-
rence after hepatectomy and was associated with re-
duced DFS [256].
HIF-1 is expressed by several human malignancies,
and overexpression has been associated with resistance
to chemotherapy and poor prognosis in some cases. OS
and DFS were significantly improved in patients with
low preoperative serum Il-8, as compared to those with
higher levels [257]. Multivariate analyses showed that Il-
8 was an independent prognostic factor for OS.
High expression of transforming growth factor beta1
(TGF-β1) is an independent prognostic factor for re-
duced survival in patients with inoperable HCC [258].Elevated urinary TGF-β1 was prognostic of shortened
survival in patients with HCC, although levels were mea-
sured at the time of diagnosis, and not all patients
underwent surgery [259].
Microsatellites (small tandem repeats of DNA bases)
are present throughout the genome. Microsatellite in-
stability (MSI) is caused by mutations in DNA mismatch
repair genes. Salvucci et al. found no association be-
tween overall MSI and prognosis but did find that a spe-
cific alteration (D16S402) was associated with a reduced
DFS [260].
Prostate cancer
Prostate cancer is the most frequently diagnosed cancer
in American men, with disease incidence increasing with
age [261]. During the past 15 years, in the era of serum
PSA screening, there has been a significant increase in
the detection of prostate cancer [262-265]. Immunohis-
tochemical staining and other methods designed to de-
tect the cellular expression levels of PSA and prosaposin
(PSAP) have not been generally successful in predicting
outcomes in prostate cancer [266-272].
Both p21 and p27 proteins, members of the Cip/Kip
family, have been studied as potential prognostic factors
in prostate cancer [267]. Maintenance of p21 immunore-
activity is associated with prolonged DFS [273]. Loss of
p27 expression has been associated with worsening dis-
ease outcomes in a number of studies [274-276]. Inter-
estingly, although increased p16 has been associated
with the presence of prostate cancer, this marker has not
yet become a useful prognostic factor. For prostate can-
cer, the results of immunohistochemical analysis-based
studies have been contradictory but have generally fa-
vored the result that overexpression of the HER-2/neu
protein is associated with an adverse outcome [277-280].
Increased expression of bFGF has also been linked to
adverse outcomes [281]. Overexpression of transforming
growth factor β (TGFβ) has been implicated in the
growth of prostate cancer cell lines and a significant re-
duction in DFS in clinical trials [282]. Up-regulation of
vascular endothelial growth factor in prostate cancer has
been associated with adverse outcomes in patients with
clinically localized disease [283].
Multidrug resistance factors have been implicated in de-
velopment of resistance of metastatic prostate cancer to
conventional cytotoxic chemotherapy [284]. Several stud-
ies have linked overexpression of the antiapoptosis protein
bcl-2 with decreased expression of the proapoptotic pro-
tein bax, and adverse outcomes in prostate cancer are as-
sociated with resistance to cytotoxic chemotherapy in
patients with hormone-refractory disease [285,286].
The recently discovered proteasome inhibitor PS-341
(bortezomib (Velcade®)) has been associated with decreased
production of bcl-2, inhibition of nuclear transcription
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chemotherapy in prostate cancer experimental systems
[287]. NFκB overexpression in prostate cancer has recently
been linked to adverse disease outcomes [288]. The NFκB
complex has a role in cancer development and progression
through its influence on apoptosis [289].
Glioma
Malignant gliomas consist of a broad range of histo-
logical entities, the majority of which respond poorly to
standard therapeutic regimens. Although radiation and
chemotherapy have been more successful to combat
childhood medulloblastoma, with 5-year survival rates
now as high as 70%–80%, the long-term side effects of
these conventional treatments can be severe [290].
Cairncross et al. documented that oligodendrogliomas,
with the loss of the short arm of chromosome 1 (1p), were
preferentially chemosensitive when treated with a procar-
bazine, lomustine, and vincristine chemotherapy regimen
[291]. These correlations with therapeutic sensitivity have
been extended to other drugs such as temozolomide and
procedures such as radiotherapy [292-294].
The expression level of MGMT and the methylation sta-
tus of the MGMT gene promoter might have a predictive
value in patients with glioblastoma treated with alkylating
drugs such as temozolomide [93,295]. Hegi et al. studied
the status of the MGMT gene promoter in tumors from
patients enrolled in a large trial that investigated the role of
concomitant temozolomide with radiation therapy vs radi-
ation therapy alone [296]. The prognostic information con-
veyed by knowledge of the MGMT methylation status
applied only to primary and not to recurrent tumors
[297,298]. MGMT repairs O6-methylguanine DNA damage
that is induced by alkylating agents such as temozolomide
(currently the mainstay of anti-glioma chemotherapy), and
strategies to overcome this resistance have been the focus
of many studies [299,300].
Prognostically, amplification of EGFR could be associ-
ated with the age of the patient, and EGFRvIII expres-
sion might enable identification of a subgroup of more
aggressive tumors [301,302]. EGFR-targeted drugs could
be used to treat patients with glioblastomas that exhibit
these characteristics in a similar fashion to some non-
small-cell lung carcinomas that contain activating EGFR
mutations and that show significant responses to the
EGFR inhibitors erlotinib and gefitinib [303].
In a follow-up study, there were improved outcomes
for patients with isocitrate dehydrogenase 1 (IDH1) and
isocitrate dehydrogenase 2 (IDH2) tumor mutations,
with a median OS of 31 months vs 15 months for pa-
tients with glioblastomas that lack these mutations, and
65 months vs 20 months for patients with anaplastic as-
trocytomas [304]. Recently, missense mutations in IDH1
were identified in a significant number of glioblastomasthat tended to occur mostly in younger patients with
more protracted clinical courses [305].
Treatment modalities and adjustment
Efficacy and toxicity of current treatment
The best therapeutic options are drugs with high efficacy
and minimal toxicity. An understanding of the cause of
disease at the molecular level is needed to discover po-
tential therapeutic targets eligible for drug intervention.
Co-evolution of potential targets and drug development
results in biomarker-driven therapies. Transformed cells
become hypersensitive to specific inhibitors that target
the deregulated oncogenic stimulus. This hypersensitiv-
ity is the basis of targeted therapies [306].
Pharmacogenetics to predict treatment outcome
Prediction of causative tumor abnormalities, markers of
drug resistance, and pharmacokinetics markers are re-
quired to select and manage treatment to enhance efficacy
of treatment and predict outcome. Pharmacogenetic (PGx)
datasets provide information on variations of DME and
drug targets, predicting efficacy, resistance, and/or toxicity
of specific drugs in individuals. Databases of germline gen-
etic variations associated with drug responses are available
online and maintained through international initiatives.
The PharmGKB Pharmacogenomics Knowledgbase (www.
pharmgkb.org) is managed by the PharmGKB team at
Stanford University, California, USA [307]. The Clinical
Pharmacogenetics Implementation Consortium (CPIC)
publishes peer-reviewed guidelines to translate this infor-
mation to the clinic, including genotype-guided drug dos-
ing. CPIC provides open-access, peer-reviewed, updated,
evidence-based pharmacogenetic clinical practice guide-
lines [308]. In addition, the FDA provides drug labeling in-
formation that details the required or recommended
genetic markers for informed prescribing.
The formulation of pharmacogenetic algorithms to assess
the use of the correct drug at the correct dose for a par-
ticular individual is challenging due to complex genotype-
phenotype associations, ethnic differences in allelic distri-
bution, and variable penetrance of frameworks of variants.
The FINDbase repository maintained by the GoldenHelix
Institute of Biomedical Research [309] is an example of a
large-scale initiative that aims to annotate allelic frequen-
cies in different countries and to create a repository of eth-
nic differences. Provision of pharmacogenetic datasets is
important, but the need of algorithms and guidelines is in-
strumental for clinical translation together with horizontal
actions to provide education of health providers and proper
tools to integrate the knowledge within the healthcare
system.
Administration of drugs to a randomly selected cohort
of cancer patients results in mild to lethal events due to
varying toxicity. To reduce pharmaceutical toxicity, the
Grech et al. The EPMA Journal  (2015) 6:9 Page 15 of 31implementation of genotype-guided dosing in healthcare
systems is imperative. One such example is dihydropyri-
midine dehydrogenase and the metabolism of 5-FU and
pro-drugs. Fluoropyrimidines, including 5-FU, are widely
used in the treatment of solid tumors and remain the
backbone of many combination regimens. Despite their
clinical benefit, fluoropyrimidines are associated with
gastrointestinal and hematologic toxicities, which often
lead to treatment discontinuation. 5-FU undergoes com-
plex metabolism, and DPD is the rate-limiting enzyme
of inactivation of 5-FU and its prodrugs. Several studies
have demonstrated significant associations between se-
vere toxicities by fluoropyrimidines and germline poly-
morphisms of DPD gene. To date, more than 30 SNPs
and deletions have been identified within DPD, the ma-
jority of these variants have no functional consequences
on enzymatic activity. However, the identification of
deficient DPD genotypes might help identify poor-
metabolizer patients at risk to develop potentially
life-threatening toxicities after standard doses of fluoro-
pyrimidines [2].
Mathematical modeling for oncology
Most processes found in medicine are non-linear, chaotic,
and have a high level of complexity that impose difficulties
to create a reliable mathematical model and in the use of
information technology at all stages of the treatment
process from the expression of the pathological processes
to the implementation of therapeutic interventions. Cre-
ation of self-controlled systems based on forecasts of fu-
ture medical errors is an important task.
To assess multi-parameter data, novel mathematical
models are required to process the medical process as a
complex system [310,311]. This process (cancer bio-
markers panel longitudinal changes) is described by some
of the primary indicators (imaging and immunohisto-
chemical biomarkers). Thus, primary indicators and out-
put rate are stochastic in nature and are presented as
statistical information. The “best” mathematical model of
the medical process is studied with a special algorithm to
process statistical data.
Fractal geometry is a promising modality, especially the
application of fractal analysis in complex systems of visual
diagnostics including radiology and histology data, in order
to expand its diagnostic capabilities by increasing the infor-
mation content for intelligent decision modeling to reduce
subjectivity in the perception and interpretation [312].
Processing of medical image analysis captures fractal pa-
rameters of these images to generate 3D vector and voxel
models. This approach was successfully applied to hepatic
ovarian and prostate tumors. Fractal geometry was esti-
mated as 1.67 for hepatocellular carcinoma case, 1.72 for
cholangiocarcinoma, 1.45–1.56 for complex cysts, and
1.15–1.35 for metastases [313].Current technologies: a brighter future
Single analysis for multi-cancer screening using metabolic
information in blood
Many cancer-biomarkers and screening protocols have
been proposed, but most of them are currently under clin-
ical investigation. A lot of difficulties prevent them from
becoming clinically useful, i.e., the heterogeneity of cell
types, gene expression detected within each individual
cancer patient, and different stages of disease progression.
Therefore, the effectiveness of certain screening bio-
markers or methods has to be varied with different types
of cancer. For instance, colonoscopy, sigmoidoscopy, stool
DNA, and fecal occult blood tests (FOBT) are currently
recommended as CRC screening methods [314-316].
However, these methods involve either invasive, special-
ized procedures (e.g., colonoscopy) or low sensitivity (e.g.,
FOBT). Enormous efforts have been exerted to identify
cancer biomarkers and to develop noninvasive methods
for CRC screening. However, although serum CEA levels
have been only accepted as a CRC tumor biomarker, they
cannot be a screening marker for CRC [317]. Moreover,
while advances in genomics, proteomics, and molecular
pathology have suggested many candidate biomarkers with
potential clinical value, trials to translate these research
advances from bench to bedside have been disappointing.
Currently, optimal blood markers for cancer screening are
therefore lacking.
Profiling of the metabolic changes caused by cancer
has become important for early detection. Indeed, meta-
bolic profiling has shown potential for cancer screening
[318-321]. To date, metabolic approaches that use liquid
chromatography (LC)-mass spectrometry (MS) are very
powerful to identify metabolites; however, studies dem-
onstrated the limitation in the number of identified me-
tabolites, usually no more than 100 distinct metabolites
[322,323]. Such a low number of metabolites might not
exactly reflect total metabolic changes in disease status.
Furthermore, LC-MS is not acceptable as a high-
throughput screening because of the relatively long
analytical time for each sample.
We can postulate that valuable information that re-
flect metabolic changes that depend on the types of
cancer might exist in the low-mass range less than
1,500 Thomsons (Th)—fibrinogen alpha chain, a very crit-
ical factor that represent inflammation, appeared at ~1,465
Th. Of course, one must always remember that a single
m/z value cannot indicate a protein; only corresponding
amino acid data unambiguously confirm the presence of
a protein, peptide, etc. Most low-mass metabolic ions
(LMIs) are mostly less than 800 Th. Systematic approaches
to translate metabolic changes, particularly in blood, have
already received attention; however, such information has
not been systematically obtained with matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) MS,
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nor robust as other ionization methods. Furthermore, peak
intensity does not accurately represent the quantity of a
metabolite unless stable isotope-labeled internal standards
are used for accurate quantification. However, MALDI-
TOF has several advantages compared to electrospray-
ionization (ESI)-based LC-MS with ion-trap MS, orbitrap
MS, triple-TOF and quadrupole-TOF), which require les
than a minute for one sample analysis, and more than 100
samples can be analyzed in a single target MALDI plate.
Furthermore, even if the low-mass range contains numer-
ous matrix peaks, they can be ruled out by their lower
weighting factors in a computing process as with other
metabolites affected by diet.
The first clinical trial of metabolic profiling (LOw-
Mass ion discriminant Equation (LOME)) for CRC
screening clearly showed its clinical potential [320]. LMI
information from sera collected from healthy controls
and from patients with CRC, gastric cancer (GC), breast
cancer (BRC), non-Hodgkin lymphoma, ovarian cancer,
and carcinoma in situ or advanced adenoma of the
colon. A two-stage principle component analysis and
novel algorithms were applied to LMIs that represented
metabolic compounds in serum to develop a new con-
cept of “LOME” for CRC, GC, and BRC screening. Fi-
nally, all sensitivities and specificities of LOMEs for
CRC, GC, and BRC screening showed over 90% in valid-
ation clinical set. Such overall results strongly supported
that LOME would be a powerful noninvasive tool with
high sensitivity and specificity for cancer screening.
To construct the LOMEs, a high mass tolerance (up to
300 ppm) can be adopted. Therefore, the exact mass of
selected LMIs for LOME construction could be con-
firmed and identified with high-accuracy MS. Further-
more, the pathological mechanisms responsible for
altering the low-mass metabolites in CRC patients have
to be clarified. Even with these disadvantages, clinical
trials of LOME imply several important points superior
to previous screening tools. First, combinations of mul-
tiple factors can better differentiate between cancer pa-
tients and healthy controls than one factor alone. The
LOME method uses multiple LMIs in serum to achieve
an excellent and robust cancer-screening power (for ex-
ample, CRC LOMEs showed much higher sensitivity
than FOBT). Second, each selected LMI can be identi-
fied and potentially useful as an individual biomarker for
cancer screening. There is currently high interest in reli-
able and easy‐to‐measure cancer biomarkers. The three
major LMIs in the discriminative biomarkers that com-
posed CRC LOMEs were identified, e.g., fibrinogen alpha
chain, which has previously been associated with various
different cancer types. Third, LOME might have import-
ant implications to screen not only CRC but also other
types of cancer. The versatility is the strongest advantageof LOME as well as the most-different aspect compared
to other screening methods. New LOMEs could be con-
structed for a wide range of diseases to suggest a new
paradigm for disease screening. Fourth, LOME can be
constructed with the strict criteria for quality control of
MALDI-TOF mass spectrum. Therefore, LOME can be
the strong tool to extract useful information from incon-
stant MALDI-TOF mass spectrum.
Development of single analysis for multi-cancer screen-
ing with metabolic information in blood (e.g., LOME) will
be required in the near future for better cancer treatment.
Dynamic analysis for monitoring therapy response using
circulating cell-free tumor DNA
Circulating cell-free tumor DNA (ccftDNA) could be ex-
tracted and analyzed to investigate the dynamic evolu-
tion of tumor biology, particularly under the pressure of
pharmacologic treatment. Indeed, significant amounts of
ccftDNA are present in the plasma of cancer patients
[324]. Because blood analysis of ccftDNA is relatively
easy to perform with new technological and noninvasive
platforms, ccftDNA represents a very attractive tool to
detect the presence of mutations, particularly those asso-
ciated with resistance to targeted agents, including
KRAS [31]. ccftDNA dynamics can be easily followed
and the appearance in the blood of a mutation associ-
ated with drug resistance is indicative of a genetic shift
of the tumor and suggests the interruption of treatment
and administration of alternative agents. Thus, less drug
is given to patients that are becoming nonresponsive.
Imaging cancer for screening, diagnosis, staging and
therapy response indicators
The ability to see the internal organs of the human body
in a noninvasive way is a powerful diagnostic tool of
modern medicine. Among these imaging modalities such
as X-ray, magnetic resonance imaging (MRI), and ultra-
sound, MRI and ultrasound present much less risk of
undesirable damage of both patient and examiner. Med-
ical imaging permits the physician to plan the thera-
peutic procedure more accurately before carrying it out,
to guide the intervention and more correctly locate the
position of the interventional tool with respect to the
anatomy, to monitor the intervention as it is being car-
ried out, and to control the intervention for optimum
results. Although static images are sufficient to plan ra-
diation therapy or provide some anatomical information
for surgery, real-time image guidance has been funda-
mental to the evolution of interventional procedures.
MRI is the most-effective technique to assess the type,
degree of differentiation, presence or absence of lympho-
vascular invasion and lymph node involvement. Magnetic
resonance spectroscopy (MRS) might support additional
characteristics, namely ADC and total choline, that might
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weighted MR imaging (DWI) is used as a response
biomarker in patients who undergo chemoradiation for
postoperative recurrences of cancer [325].
Positron emission tomography-computed tomography
(PET/CT) has higher sensitivity and specificity than con-
ventional anatomic modalities and is valuable to deter-
mine the extent of disease and detecting recurrent or
residual tumor [326]. In locally advanced cervical cancer,
18 F-fluorodeoxyglucose (FDG) PET/CT has become
important in the initial evaluation of disease extent. 64Cu-
labeled diacetyl-di(N(4)-methylthiosemicarbazone) is taken
up by hypoxic tissues, which might be valuable for
prognostication and radiation treatment planning [327].
However, extensive use is subject to financial, legal, and
radiation safety implications associated with whole-body
PET/CT for cancer screening, diagnosing, staging, and re-
staging cancer and for monitoring treatment effects. In
spite of advocating CT, PET, or PET/CT for whole-body
screening, recommendations and decisions regarding can-
cer screening should be based on reliable data, not good
intention, assumptions, or speculation [328]. For these
reasons, actually, we still cannot consider PET as a per-
spective screening tool for a number of cancer locations.
Elastography data—promising noninvasive biomarker.
Today, a new noninvasive method of examination,
sonoelastography (SEG), which is based on the ultrasonic
examination of tissue softness, is constantly under devel-
opment. The technology is based on the fact of inverse
scattering ultrasonic signal in mild compression and re-
laxed insonated tissue during the study [329]. Thomas
et al. found that it was possible to diagnose malignant tu-
mors of the cervix with elastography [330].
Angiogenesis visualization. Angiogenesis in cancer helps
fulfill the metabolic demands of the progressing tumor
and plays a critical role in tumor metastasis. Therefore,
various imaging modalities have been used to cha-
racterize tumor angiogenesis. Micro-CT (μCT) is a
powerful tool to analyze the tumor microvascular
architecture at micron-scale resolution, MRI with its
sub-millimeter resolution is useful for obtaining in vivo
vascular data (e.g., tumor blood volume and vessel size
index) [331]. However, integration of these microscopic
and macroscopic angiogenesis data across spatial reso-
lutions remains challenging. Laboratory biomarkers
that represent vascularization might be conjoined with
imaging data in particular for vasospasm and conges-
tion assessment.
Optoacoustic imaging. The optoacoustic method was
suggested in the diagnosis of cancer. The method is
based on the ability of nanoparticles under the influence
of near-infrared light to allocate heat. Nanoparticles can
be passed around tissues and turned into sound waves
that might be registered by an ultrasound receiver.Optoacoustic phenomena and other still hidden proper-
ties of nanomaterials open new views on personalized
and predictive approach and could be the basis to create
pharmacodynamic biomarkers ideal for use in diagnos-
tics and prognostics and to suggest the likely outcome of
a disease irrespective of treatment.
Development predictive biomarkers and relevant screening
programs with focus on early diagnosis
Evidence-based public health has its roots in evidence-
based medicine and arose as a need for evidence-based
decision making in public health and radiology [332]. In
consequence, trials that focus on intermediate endpoints
(precancerous lesions or suitable biomarkers, e.g., ultra-
sound for atypical hyperplasia, prostate cancer, sonoelas-
tography for breast, thyroid, soft tissue lesions) have
become more widely accepted, especially because of a
better understanding of the use of surrogate markers in
cancer research and the fact that they can be carried out
in a shorter period of time and with greater statistical
power [333,334]. Collecting integrated biomarkers in-
cluding imaging scans and data, obtained from relevant
questionnaires to suggest relevant screening programs,
allow outcomes such as avoid unnecessary imaging pro-
cedures. For instance, transvaginal ultrasonography has
a poor positive predictive value but has a high negative
predictive value to detect serious endometrial diseases in
asymptomatic post-menopausal women [335,336].
Patient profile standardization
During the last decades, we were in a silent revolution
based on the fact that all processes in image-based radi-
ology have become entirely digital. Digitalization is the
starting point for measurement. And just as measurement
has allowed the natural sciences to progress, it enables
medicine to progress. Relevant radiology (ultrasound,
MRI, PET, CT, endoscopy) database modeling is per-
formed with a scientific purpose to publish research re-
sults, and for processing of records, introspection, and the
doctor of any other type of analysis (including financial).
The key features of reliable statistical analysis are correct
logging and archiving of research results.
Imaging modalities guidelines
A national effort to support comprehensive cancer con-
trol outlines national and state level success in compre-
hensive cancer control and provides a call to action to
public, private, and non-profit organizations, govern-
ments of all levels, and individuals to renew their com-
mitments to reduce the burden of cancer. The great
majority of states have recommended European or na-
tional guidelines for use of imaging [337]. However, still
the imaging modalities that involve ionizing radiation
(radiography and nuclear medicine) were included in the
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ionizing radiology modalities (US, MRI) were present in
only 75% of guidelines.
Hereby we recommend to develop guidelines to consider
the PPPM approach with safe and effective screening and
diagnostic algorithms and to consider needs of children
and for pregnant women and elderly to adhere to the vi-
sion of many involved societies such as EPMA cancer and
the specialized (such as neurology, urology, gynecology)
societies in a multidisciplinary PPPM scope to suggest a
balanced, well-reasoned, and evidence-supported applica-
tion of different imaging modalities, by considering safe
clinical validity, and to increase nonionized and effective
modalities (such as ultrasound) in protocols. As further
developments of cancer imaging might be considered for
the improvement of cancer screening and diagnosis, we
develop techniques upon utilizing physical properties like
artifacts in diagnostic ultrasound and MRI to expand and
improve image-guided treatments, robotics, and patient
profile standardization, modeling the image-guided min-
imally invasive diagnostic and therapeutic interventional
procedures with relevant education programs.
Nanotechnologies – the challenge for advanced diagnosis,
treatment and prevention
Advances in nanoscience, nanotechnology, and nanome-
dicine lead to the construction of new materials and de-
vices for various scientific and therapeutic purposes,
which are applicable in molecular diagnostics, nanodiag-
nostics, and improvements in the discovery, design, and
delivery of drugs, including nanopharmaceuticals. The
application of nanoparticles that allow the combination
of therapy and diagnosis, known as theranostic, has re-
ceived increasing attention in biomedicine. Current evi-
dence suggests that nanocrystalline ceria is a unique
multifunctional material, which can be the basis to de-
sign a variety of drugs that promise for use in cancer
therapy and diagnostics [338]. Many practical applica-
tions of ceria are based on its ability to protect living
systems from oxidative stress of different origin, acting as
an artificial analog of oxidoreductases, including super-
oxide dismutase, peroxidase, catalase, etc. The redox activ-
ity of nanocrystalline ceria is largely dependent on the
particle size and composition of the environment, which
makes it possible to fine-regulate the antioxidant and pro-
oxidant properties of the preparations for redox therapy.
Nanocrystalline ceria are promising for application to
tumors of viral origin. Of particular interest is the joint
use of hybrid materials based on nanocrystalline ceria and
protein anticancer drugs to increase the therapeutic effect-
iveness and reduce toxic side effects. The photoprotective
and radioprotective effect of nanocrystalline ceria opens
up broad prospects for its use in photodynamic therapy
and radiotherapy of tumors. The pH-sensitive propertiesof nanoceria provide an opportunity to create a means
of delivery of “smart” drugs, such as antitumor nano-
preparations that release the drug in the right place at
the right time [339].
Finally, nanocrystalline ceria, different CeO2-based solid
solutions (including gadolinium (Gd)-containing solid so-
lutions), and CeO2 nanoparticles with the surface modified
with various ligands can be used for multimodal diagnosis
of cancer, including malignant cell imaging and MRI and
SPECT diagnostics. When choosing the material of nano-
particles for diagnosis, one should take into account,
above all, the possibility to use them in existing diagnostic
methods and equipment. For MRI, nanoparticles that con-
tain Gd compounds [340] or superparamagnetic iron
oxide Fe3O4 (SPIO) are used as a contrast agent. Nanopar-
ticles of iodine derivatives, noble metals [341], some non-
toxic heavy metal oxides, and rare earth compounds [342]
might be considered for use as X-ray contrast agents.
For targeted delivery of nanoparticles to tumor, targeting
ligands with tropism for tumor cells are used, including
folic acid, VEGF, and sugars. Possibility of penetration of
the drug into the cell is determined by the membrane af-
finity of nanoparticles; this affinity essentially depends on
the surface charge of a nanoparticle. Nanoparticles of vari-
ous types are widely used for drug delivery into tumor
cells. The drug (e.g., an antibiotic, a cytotoxic agent or
cytostaticcisplatin, and doxorubicin) can be located inside
a nanoparticle and on its surface [343,344]. In the first
case, such a “nanocapsule” should self-destruct in a tumor
cell to release the drug [345]. In the second case, the
medicine serves as yet another (third) surface ligand. A
nanoparticle itself either is an inert carrier or also performs
additional functions, for example, of contrast agent [343].
The drug on the surface of the nanoparticle can be add-
itionally encapsulated, for example, into the cavity of the
cyclodextrin molecule. In particular, cyclodextrin is used to
fix the adamantane-PEG-transferrin conjugate on the sur-
face of nanoparticles and to deliver small interfering RNAs
(siRNAs) in gene therapy of cancer [339]. Among the
clinically approved nanocomposites for drug delivery in
chemotherapy of tumors are liposomal formulations of
cytarabine, doxorubicin (Myocet®) and PEG-doxorubicin
(Doxil®), daunorubicin (DaunoXome®), polymeric nano-
particles of methoxy_PEG-L,D-polylactide with taxol
(Genexol_PM®) and PEG-L-asparaginase (Oncaspar®),
paclitaxel albumin (Abraxane®) [345], among others.
Integration of omics to pilot the molecular networks for
PPPM in human pituitary tumors: proof-of-principle models
Pituitary tumor is a complex whole-body disease that al-
ters levels of gene (genome), mRNA (transcriptome),
protein (proteome), and metabolite (metabolome) and
that involves multi-factors, multi-processes, and multi-
consequences [346]. Individual variation is involved in
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therapy, and late-stage diagnosis/therapy. The develop-
ment of omics (genomics, transcriptomics, proteomics,
and metabolomics) and systems biology has promoted one
to change paradigms from a traditional single factor strat-
egy to multi-parameter systematic strategy [346,347]. A
new integrative opinion has been brought in the model of
predictive screening and prognostic assessment of pituit-
ary tumors that previously only depended on the changes
of serum single-hormone change and pituitary imaging.
The therapeutic model of cancer has changed from the
general radiotherapy and chemotherapy to personalized
strategy. The development of PPPM is substantially chan-
ging the understanding, prediction, prevention, and thera-
peutic model of pituitary tumors from a systematic to a
comprehensive point of view.
From the point of view of systematic strategies for
PPPM in pituitary tumors, it is necessary to systematically
study the changes in genome, transcriptome, proteome,
peptidome, and metabolome in individual pituitary tumor
tissue and body-fluid (cerebral spinal fluid (CSF); serum/
plasma) [347]. Systems biological strategies [348-353] will
be used to integrate all experimental data and all clinical
information of individual to propose the corresponding
molecular networks specific to an individual pituitary
tumor for efficient prediction screening, early-stage diag-
nosis, prognostic assessment, and individualized preven-
tion and therapy.
The genome, transcriptome, proteome, peptidome, and
metabolome are different among individual tumors and
between tumor and normal, and the molecular network
alters among individuals and between tumors and normal.
Eight different levels of project studies will be necessary to
achieve these objectives for PPPM practice in pituitary
tumors.
Establish a reliable biobank of pituitary tumors
Two core aspects of the biobanking discipline are quality
and good governance of biospecimen [354]. The reliable
biobank and standardized procedure of collection and
storage of biospecimen are the basis that guarantees
one to realize large-scale molecular research in cancer
[355-360]. For each pituitary tumor, its tumor tissue,
CSF, blood, and all clinical information are required for
eventual studies.
Establish molecular networks at the level of the genome of
pituitary tumor
Breakthroughs of genomics technology have facilitated
large-scale sequencing of the whole genome, genome-
wide modification analysis, and transcriptome arrays in
individual patients [361-363]. The complexity of those
large-scale genome sequencing data might result from
the heterogeneity of cell materials that might provide anaveraging of results among tumor cells, stroma, endo-
thelium and blood cells and lead to longstanding gen-
omic instability [364,365]. High-throughput sequencing
now allows one to sequence more numbers of patients
and will facilitate the construction of genome-based
molecular networks to allow better therapeutic deci-
sions [361,366].
Establish molecular networks at the level of the
transcriptome of pituitary tumor
Transcriptomics describe the global mRNA expression of
a particular tissue and yield transcriptional difference data
between two or more states [367,368]. It is essential to in-
terpret the functional elements of the genome, reveal mo-
lecular constituents of cells and tissues, and understand
the development of cancer. To construct transcriptome-
based molecular networks, high-throughput platforms are
today available to analyze and quantify the entire tran-
scriptome profile of an organism [369].
Establish molecular networks at the level of the proteome
of pituitary tumor
Proteomics is mainly used to identify, characterize, and
quantify proteins in a defined biological system (organelle,
cell, tissue, biofluid, or whole organisms) and has been
considered as a powerful tool to study human tumors be-
cause of its ability to detect a large number of proteins in
a short period of time [370-373]. The isobaric Target
for Relative and Absolute Quantification (iTRAQ)-based
quantitative proteomics is a commonly used quantitative
proteomic methodology [374]. iTRAQ-based quantitative
proteomics obtains protein expression profiles among
individual tissue, blood cell, CSF, and plasma. Systems
biology techniques are employed to construct proteome-
based molecular networks.
Establish molecular networks at the level of the peptidome
of pituitary tumor
Peptidomics is mainly used to identify, characterize, and
quantify peptides in a body fluid and has been considered
as a powerful tool to recognize a set of body fluid peptide
biomarkers because body fluid contains peptides that re-
sult from tumor pathophysiological process, is a window
that reflects tumor pathophysioligical states and its meta-
bolic molecular networks, and would effectively serve for
prediction, diagnosis, and prognosis assessment [375,376].
Establish metabolic networks at the level of the
metabolome of pituitary tumor
Metabolomics is useful in the prediction of the effect of
metabolic pathways on anticancer drugs in tumor patient
[377]. It can measure global sets of low-molecular weight
metabolites as indictors of physiological or pathological
states. These large-scale metabolomic data can contribute
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regulatory networks able to predict drug effects [378,379].
Establish integrative molecular networks for pituitary tumor
Gene (genome), mRNA (transcriptome), protein (prote-
ome), peptide (peptidome), and metabolite (metobolome)
are mutually associated in an organism [346]. It is ne-
cessary to integrate different levels of molecule profile
variations to construct integrative molecular networks for
a pituitary tumor. Moreover, how those omics data-
molecular networks link to clinical information is also im-
portant. Computation biology and systems biology can
achieve those goals to systematically and comprehensively
elucidate molecular mechanism and biomarkers for pi-
tuitary tumors.
Evaluate the molecular networks for prediction screening,
early-stage diagnosis, prognostic assessment, and
individualized prevention and therapy
The molecular networks are evaluated for accuracy, sensi-
tivity, and specificity in the prediction screening, early-
stage diagnosis, and prognostic assessment. The key
molecular targets derived from molecular networks are
useful for drug design and new drug development for effi-
cient prevention and therapy.
A comprehensive and systematic analysis and validation
of molecular networks at genome, transcriptome, pro-
teome, peptidome, metabolome, and interactome levels
completely clarify variations in molecular networks com-
mon and specific to the stratified and/or individualized
pituitary tumors for the accurate and effective prediction,
prevention, and personalized treatment for pituitary
tumor to achieve the real PPPM practice. Moreover, a
pituitary tumor is a model tumor in this section and all
concepts, strategies, and techniques used for pituitary
tumors can be easily translated to the study of other
cancers.
Reliable cancer longitudinal in vivo animal models
Animal models have allowed the study of many diseases
in the early stages, as well as investigation of the mecha-
nisms of the pathogenesis and the effects of drug inter-
vention. Mouse and rat models have been and still
remain instrumental to reveal complexities of human
cancer biology. An ideal animal model for any disease in
humans should follow five characteristics: (1) mimic the
human disease; (2) allow studies in chronic, stable dis-
ease; (3) produce symptoms that are predictable and
controllable; (4) satisfy economical, technical, and ani-
mal welfare considerations; and (5) allow measurement
of relevant cardiac, biochemical, and hemodynamic pa-
rameters. Because cardiovascular disease is uncommon
in young humans but markedly increases with age, age-
related changes of an animal should be considered.The mouse (mus musculus) has emerged as the model
organism of choice to study tumor development because
the mouse and human are similar in many aspects such
as basic physiology and genome size. The challenge for
PPPM is to design the most clinically valid models in-
herent to the complexity of disease and similarity to hu-
man organism modeling, considering collateral cancer-
associated diseases. Many studies with mouse and rat
models are limited by the inability to gather experimen-
tal information in vivo and noninvasively. Small animal
imaging solves many inaccuracies in the modeling [380].
Humanized mouse models of cancer, where human cells
are introduced into immune-compromised mice and
contribute/give rise to human tissues in the mouse, are
of two types: (a) genetic-chimeras, where human genes/
chromosomes are introduced into the mouse genome,
and (b) cellular-chimeras. These developments could
lead to better understanding of the various stages of
cancer development and potentially lead to the devel-
opment of more relevant pre-clinical models for thera-
peutic development [381].
Implementing personalized medicine
The challenge of translating evidence-based discoveries to
the clinical setting requires multidisciplinary approaches.
The success of clinical studies depends on the proper clas-
sification of patients, use of the appropriate therapeutic
groups for the studies, and proper design of the study.
Meta-analysis between different studies is hindered by the
lack of harmonization of variables. Drug efficacy and
toxicity measures, the use of therapy modalities, and drug-
administration protocols vary significantly. Hence a well-
defined set of outcome measures should be adopted to
allow meta-analysis [382]. Another variable is the clinical
reporting of a phenotype. eTools should be adopted to
harmonize the clinical reports, ideally with well-defined
phenotypic and scoring methods. In addition, methods to
correlate the studied marker with drug responses vary
considerably. This can be easily overcome if the data is re-
corded using well-defined and set parameters that allow
further analysis.
Education of healthcare providers is also an area that
required continuous input. Implementation of genomic
medicine suffers from the creation of a knowledge-
base. Defining the required competencies within the
healthcare system and creation of appropriate educa-
tional tools awaits a better integration of the data gen-
erated by genetic tests into the healthcare system.
Currently, evidence-based associations are generated by
comparing cohorts under genetic-guided therapy and
those under clinical-guided care to measure the effect-
iveness of genetic tests. These comparisons are very
informative, but delays treatment [383]. Due to this limita-
tion, case–control studies are preferred. The translation of
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signs [384] to allow data sharing and minimize the vari-
ability of pharmacogenetic results [385].
Implementation of specific tests should be justified on the
basis of the clinical utility and the level of evidence. The
CPIC, under the governance of the Pharmacogenomics
Research Network (http://www.pgrn.org) and the Pharma-
cogenomics Knowledge Base [386], provides open-access,
peer-reviewed, updated, evidence-based pharmacogenetic
clinical practice guidelines [308]. Recently, the Italian Soci-
ety of Pharmacology in conjunction with the Italian Associ-
ation of Clinical Oncology issued a formal recommendation
for the routine use of pharmacogenetic testing of DPD and
UGT in clinical oncology practice [http://www.aiom.it].
The development of technologies and integrative in-
formation systems to provide a given healthcare system
with optimized and sustainable testing protocols is re-
quired. The technology should provide results in a clear
and conclusive report that is compatible with the health-
care data system. Adoption of electronic health records
(EHRs) to store and interpret genetic results, based on
clinically validated algorithms, provides a tool that will
allow genetic-based informed decisions. The goal of this
activity is to consolidate technology and methods and
provide the healthcare system with a technology that will
last for years and that will be fully supported for the
same period of time. It is important to note that health-
care systems cannot change technologies frequently!Projected outcomes and recommendations
Background and general comments
The members of the EPMA PPPM in Cancer Group have
years of experience in the many different fields of cancer
that are discussed in this position paper. The group devel-
oped this report after EPMA/PPPM meetings and multiple
rounds of e-mails to develop their individual and collective
thoughts, outlines, and rough drafts.Outlook
Cancer is a multifactorial disease that encompasses the
genome, transcriptome, proteome, metabolome, and other
to-be-discovered “-omes”.
Everybody would like to have a “magic bullet” bio-
marker that could be effectively used to quickly discover
and accurately diagnose each cancer type and would lead
to treatment that would effectively and completely oblit-
erate each cancer at a very early stage. That desire to
have a biomarker drives all of the clinical and basic re-
search in cancer. However, as we delve more deeply into
the complexity of cellular processes and develop more
accurate and more precise analytical methods and
pharmacological interventions, it becomes abundantly
clear that, instead of only one biomarker, a panel ofbiological markers is needed to effectively diagnose and
treat each cancer.
One must recognize the need for essential material to
study. Cancer tissue is heterogeneous, and undergoes a
quick evolution of mutation accumulation through gen-
omic instability. Investigation of causative mutations in
the development of the disease with tumor material is
very complex. Understanding the etiology of primary le-
sions requires retrospective studies with matched blood
and tissue at different stages of the tumor; hence, bio-
banks are important. Biobanking protocols should be
harmonized and should include details of sample acqui-
sition. To study proteins, it is important to rapidly place
a surgical specimen into acid plus liquid nitrogen, to
quickly stop metabolic processes, enzyme activity, and
interconversions. Specialized protocols should be made
available and properly implemented.
The future is quite bright and promising for biomarker
discovery. Although it will not be easy to discover all
needed biomarkers, clinical and research methods and
instrumentation to study cancer become more powerful.
Concomitantly, the development of effective pharmacol-
ogy treatments will keep apace and derive input from
the collection of -omics studies.
Recommendations
The recommendations of this PPPM in Cancer Group
are to prepare a priority list of cancer risk factors that
can be measured accurately using current technologies,
formulate healthcare economic studies in different coun-
tries to define and justify expenses to measure risks as
against healthcare costs, and prepare guidelines to moni-
tor risks and define harmonized healthcare strategies to
reduce the healthcare burden [387]. This potential de-
liverable ties in with various other actions that are re-
quired to ensure early diagnosis and a better quality of
life for patients and to reduce cancer incidence and can-
cer mortality rate. Supportive actions include the devel-
opment of guidelines to implement effective screening
and diagnostic algorithms, expand and improve image-
guided treatments, modeling the image-guided minim-
ally invasive diagnostic and therapeutic interventional
procedures, proper measures of efficacy and toxicity of
current treatment including implementation of pharma-
cogenetic analysis, adjustment of treatment modalities
based on pre-defined algorithms, and longitudinal ac-
tions such as the provision of relevant education pro-
grams, technological innovation, and medical research
followed by evidence-based implementation to the clinic.
Multidisciplinary approaches are required as indicated
in this position paper. We recommend a holistic ap-
proach to reduce cancer healthcare burden. For instance,
other disorders and their treatment are also a risk factor
for cancer initiation. Chronic inflammation of the bowel
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approach in treatment adjustment is considered as safe for
the patient, but evidence should be collated to understand
if this approach promotes development of cancer. Hence,
we recommend to develop guidelines to stratify patients
using well-defined biomarkers, measuring risks associated
with cancer development, and provide actionable solutions
to reduce such risks. Implementation of personalized
medicine is challenging, and translating evidence-based
discoveries to the clinic requires well-defined guidelines.
Many cancers will greatly benefit from a concerted effort
to significantly and quickly increase research funding in
cancer, develop new panels of biomarkers, develop more-
effective pharmacological agents, and increase each indi-
vidual’s participation in their healthcare [388]. The PPPM
concept is gaining worldwide acceptance and momentum,
and results are impressive. Because of the extensive world-
wide momentum of clinical and basic research in cancer,
the time is ripe for a quantum increase in the amount of
money devoted to investigator-initiated cancer research.
That recommendation is obviously not only scientific or
clinical but also political because it clearly invites every-
body involved with cancer to participate in that exciting
activity. Virtually, every person knows somebody who has,
or has died from, a cancer. Most people feel helpless, con-
fused, angry, etc. when confronted with a cancer in their
life or in somebody close to them. The most effective ap-
proach to increase funding is for each person, patient,
family member, researcher, neighbor, grandparent, inter-
ested person, etc. to write directly to representatives in
their government’s funding agency. In the U.S.A., the
most-effective person to write to is a representative and
senator. We know that this method works because the
doubling of the U.S.A. National Institutes of Health re-
search budget 15 years ago was due in large part to the
widespread outpouring of letters written to the congress
by researchers and those touched by cancer.
Conclusion
The overall goal of EPMA and PPPM cancer is to signifi-
cantly decrease the number of deaths, continuously im-
prove early detection, develop state-of-the-art diagnosis
and treatment, improve the quality of life of patients,
and develop easy-to-use kits for diagnosis as clearly
stated in the General Report and Recommendations in
Predictive, Preventive and Personalised Medicine 2012:
White Paper of the European Association for Predictive,
Preventive and Personalised Medicine [389]. It is import-
ant to study the mechanisms that lead to cancer in order
to effectively prevent it. Much more basic research is re-
quired. Each individual is, by definition, unique. Each
person’s cancer is unique. Each treatment is unique. It is
important to predict therapy resistance and relapse. Each
individual will respond differently to treatment. There isno “one treatment fits all cases.” Each patient must be
monitored to accurately determine their response to
treatment.
In summary, while discussing implementation of per-
sonalized medicine, governments and healthcare systems
should be mindful of the potential for flaws in delivery
of adequate care and thus ensure that new developments
in therapy are available to all patients and not just to a
select few. If this issue is addressed comprehensively by
EPMA in developed nations (e.g., the EU) to start with,
we can then be confident of rolling this approach out to
less wealthy nations, globally.
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